OBJECTIVES: The objective is to carry out an economic analysis comparing lebrikizumab vs. dupilumab in Austrian patients with moderate to severe Atopical Dermatitis (AD) from local SHI funds perspective.

METHODS: The Austrian model is based on the cost-effectiveness models in AD by NICE appraisal TA814. Lebrikizumab proved to be assessed in indirect clinical comparisons as similarly effective and safe to dupilumab (Standard of Care). In the base case, it is assumed that all patients are treated without corticosteroids ("monotherapy"). The model refers to patients from the age of 12 with a body weight of at least 40 kg, with moderate to severe forms of atopic dermatitis (AD), in whom systemic treatments were not sufficiently effective, were not tolerated or were contraindicated. For the first year of treatment, it contains a decision tree; from the second year, a Markov model. Austrian tariffs and prices from January 2024 are used.

RESULTS: The base case is a lifelong model, with 3% discounting and combination therapy with topical corticosteroids if needed and shows that lebrikizumab has a cost advantage of €2,409 compared to dupilumab.

CONCLUSIONS: In summary lebrikizumab proves to be economically recommendable compared to dupilumab in a cost advantage over dupilumab in lifelong observation.